

EVALUATION OF AGGRESSIVENESS OF DIFFERENT HISTOLOGICAL TYPES OF AMELOBLASTOMAS USING p170 AND p300 AS A NOVEL IMMUNOHISTOCHEMICAL MARKERS

Thesis

*Submitted to the Faculty of Oral and Dental Medicine, Cairo
University, for fulfillment of the requirements for the degree of
Doctor of Philosophy in Basic Dental Sciences
(Oral Pathology).*

By

AMR HELMY ELBOLOK

B.D. Sc., M. D. Sc. (Cairo University)

***FACULTY OF ORAL AND DENTAL MEDICINE
CAIRO UNIVERSITY***

2006

CONTENTS

Chapter	Page
I. INTRODUCTION.....	1
II. REVIEW OF THE LITERATURE	
a. Ameloblastoma.....	3
b. p170.....	14
c. p300.....	26
d. Immunohistochemical studies on ameloblastomas.....	39
III. AIM OF THE STUDY.....	46
IV. MATERIAL AND METHODS.....	47
V. RESULTS.....	53
a. Clinical Results	53
b. Microscopic Findings.....	56
c. Evaluation of Immunohistochemical Reactions by the Image Analysis Computer System.....	59
d. Photomicrographs of Results	65
e. Bar Charts of the Studied Cases	90
f. Tables of statistical results.....	94
VI. DISCUSSION.....	100
VII. CONCLUSIONS.....	110
VIII. SUMMARY	112
IX. REFERENCES.....	114

LIST OF FIGURES

Figure	Page
Figure 1: ABCB1 maps on chromosome 7, at 7q21.1.....	14
Figure 2: schematic model of p-glycoprotein.....	17
Figure 3: three dimensional hypothetical structure of p-gp.....	17
Figure 4: gene EP300 maps on chromosome 22, at 22q13.2.....	27
Figure 5: chemical analysis of p300.....	29
Figure 6: role of p300 in preventing cancer.....	33
Figure 7: The method of detection of immuno reactivity in p300.....	51
Figure 8: The way of measurement of the area of immunoreactivity by the computer system after being masked by a blue binary color.....	51
Figure 9: the grey delineated image of p300	52
Figure 10: The way of measurement of the optical density of immunoreactivity by the computer system after being masked by a blue binary color.....	52
Figure 11: Case of acanthomatous follicular ameloblastoma (H&E X 100).	65
Figure 12: Case of acanthomatous follicular ameloblastoma (H&E X 100).	65
Figure 13: Case follicular ameloblastoma (H&E X 40).	66
Figure 14: Case of muticystic follicular ameloblastoma (H&E X 100).....	66
Figure 15: Case of follicular ameloblastoma (anti p170 antibody x 200).....	67
Figure 16: Case of follicular ameloblastoma (anti p170 antibody x 400).....	67
Figure 17: Case of follicular ameloblastoma (anti p170 antibody x 200).....	68
Figure 18: Case of follicular ameloblastoma (anti p170 antibody x 400).....	68
Figure 19: Case of follicular ameloblastoma (anti p170 antibody x 200).....	69
Figure 20: Case of follicular ameloblastoma (anti p170 antibody x 200).....	69
Figure 21: Case of follicular ameloblastoma (anti p170 antibody x 200).....	70
Figure 22: Case of follicular ameloblastoma (anti p170 antibody x 200).....	70
Figure 23: Case of follicular ameloblastoma (anti p170 antibody x 400).....	71

Figure	Page
Figure 24: Case of follicular ameloblastoma (anti p170 antibody x 200).....	71
Figure 25: Case of follicular ameloblastoma (anti p170 antibody x 400).....	72
Figure 26: Case of follicular ameloblastoma (anti p170 antibody x 400).....	72
Figure 27: Case of follicular ameloblastoma (anti p170 antibody x 200).....	73
Figure 28: Case of follicular ameloblastoma (anti p170 antibody x 400).....	73
Figure 29: Case of follicular ameloblastoma (anti p170 antibody x 400).....	74
Figure 30: Case of follicular ameloblastoma (anti p170 antibody x 200).....	74
Figure 31: Case of follicular ameloblastoma (anti p300 antibody x 200).....	75
Figure 32: Case of follicular ameloblastoma (anti p300 antibody x 200).....	75
Figure 33: Case of follicular ameloblastoma (anti p300 antibody x 200).....	76
Figure 34: Case of follicular ameloblastoma (anti p300 antibody x 400).....	76
Figure 35: Case of follicular ameloblastoma (anti p300 antibody x 400).....	77
Figure 36: Case of follicular ameloblastoma (anti p300 antibody x 400).....	77
Figure 37: Case of follicular ameloblastoma (anti p300 antibody x 200).....	78
Figure 38: Case of plexiform ameloblastoma (H&E X 100)	78
Figure 39: Case of plexiform ameloblastoma (anti p170 antibody x 200)	79
Figure 40: Case of plexiform ameloblastoma (anti p170 antibody x 200)	79
Figure 41: Case of plexiform ameloblastoma (anti p170 antibody x 200)	80
Figure 42: Case of plexiform ameloblastoma (anti p170 antibody x 400)	80
Figure 43: Case of plexiform ameloblastoma (anti p170 antibody x 200)	81
Figure 44: Case of plexiform ameloblastoma (anti p170 antibody x 200)	81
Figure 45: Case of plexiform ameloblastoma (anti p300 antibody x 200)	82
Figure 46: Case of plexiform ameloblastoma (anti p300 antibody x 200)	82
Figure 47: Case of plexiform ameloblastoma (anti p300 antibody x 200)	83

Figure	Page
● Figure 48: Case of unicystic ameloblastoma (anti p170 antibody x 100)	83
● Figure 49: Case of unicystic ameloblastoma (anti p170 antibody x 400)	84
● Figure 50: Case of unicystic ameloblastoma (anti p300 antibody x 100)	84
● Figure 51: Case of unicystic ameloblastoma (anti p300 antibody x 200)	85
● Figure 52: Case of Ameloblastic carcinoma (H&E X 200)	85
● Figure 53: Case of Ameloblastic carcinoma ((H&E X 200)	86
● Figure 54: Case of Ameloblastic carcinoma (H&E X 400)	86
● Figure 55: Case of Ameloblastic carcinoma (H&E X 400)	87
● Figure 56: Case of Ameloblastic carcinoma (H&E X 200)	87
● Figure 57: Case of Ameloblastic carcinoma (anti p170 antibody x 200)	88
● Figure 58: Case of Ameloblastic carcinoma (anti p300 antibody x 400)	88
● Figure 59: Case of Ameloblastic carcinoma (anti p300 antibody x 400)	89
● Figure 60: Mean area % of p170 immunoreactivity in ameloblastoma	90
● Figure 61: Mean optical density of p170 immunoreactivity in ameloblastoma...	91
● Figure 62: Mean area % of p300 immunoreactivity in ameloblastoma.....	91
● Figure 63: Mean optical density of p300 immunoreactivity in ameloblastoma...	92
● Figure 64: comparison of Mean area % of p170 and p300 immunoreactivity in ameloblastoma	93
● Figure 65: comparison of Mean optical density of p170 and p300 immunoreactivity in ameloblastoma	93

LIST OF TABLES

TABLE

PAGE

- Table 1: Regional variation in P-glycoprotein expression22
- Table 2: histopathological diagnoses and number of studied cases.....47
- Table 3: monoclonal antibodies used.....47
- Table 4: Description of the universal kit.....48
- Table 5: clinical data of the studied cases.....53
- Table 6: summary of the clinical data of the studied cases.....56
- Table 7: descriptive statistics of the mean area% and mean grey of p170 within different groups of ameloblastomas.....94
- Table 8: descriptive statistics of the mean area% and mean grey of p300 within different groups of ameloblastomas.....94
- Table 9: "t" test for mean difference between area% of p170 and p300.....95
- Table 10: "t" test for mean difference between mean grey of p170 and p300....95
- Table 11: "t" test for mean difference between area% of p170 and p300.....95
- Table 12: "t" test for mean difference between mean grey of p170 and p300.....95
- Table 13: "t" test for mean difference between area% of p170 and p300.....96
- Table 14: "t" test for mean difference between mean grey of p170 and p300....96
- Table 15: "t" test for mean difference between area% of p170 and p300.....97
- Table 16: "t" test for mean difference between mean grey of p170 and p300.....97

- Table 17: Duncan test to measure the variance of area% for p170 reaction to the different groups of ameloblastomas97
- Table 18: Duncan test to measure the variance mean grey for p170 reaction to the different groups of ameloblastomas98
- Table 19: Duncan test to measure the variance of area% for p300 reaction to the different groups of ameloblastomas.....98
- Table 20: Duncan test to measure the variance mean grey for p300 reaction to the different groups of ameloblastomas99
- Table 21: summary of results for tables 17, 18, 19, 20.....99

ACKNOWLEDGEMENTS

In the beginning I would like to express my sincere thanks to all the staff members of the Department of Oral Pathology, Cairo University, for their kind support during performance of this work.

I am deeply grateful to Dr. Heba Ahmed Farag, Professor of Oral Pathology, Cairo University, for her valuable guidance, continuous scientific supervision and spiritual encouragement during the entire course of this work.

I also offer my deep gratitude and thanks to Dr. Gamal El Din Mohamed Fathalla, Assistant Professor of Oral Pathology, Cairo University, for his faithful assistance, indefatigable efforts, and great help during the course of this work.

Last but by no means least; I sincerely offer my heartfelt thanks and appreciation to my mother, my wife and my brothers who

stood by me during this work through their
spiritual support and encouragement all
along my way.

LIST OF ABBREVIATIONS

- AB: ameloblastoma
- ABC transporters: adenosine triphosphate-dependent membrane transporters
- AMBN: Ameloblastin protein
- AP-1: promoter-bound transcription factor
- ATP: adenosine triphosphate
- CBP = CREB: cyclic-AMP responsive element binding protein
- CDK: cyclin dependent kinase
- c-jun: signal transducing transcription factor
- c-myc: nuclear transcription factor
- DNR: daunorubicin
- DOX: doxorubicin
- E1A : adenovirus E1A gene encoding for adenovirus oncoprotein
- E2F: nuclear transcription factor
- EGFR: epidermal growth factor receptor
- HIF1A : hypoxia-inducible factor 1 alpha
- htert: telomerase reverse transcripase
- ICAM-1: intercellular adhesion molecule - 1
- Ki-67: Protein expressed in all phases of cell cycle except G0, a good marker for proliferation
- MAPK: mitogen-activated protein kinase
- mdm: murine double minutes

- MDR: multiple drug resistance
- MK: Midkine
- MMPs: matrix metalloproteinases
- mRNA: messenger ribonucleic acid.
- MSD: membrane-spanning domain
- MSI+: Microsatellite instability
- myo-D: Myogenic regulatory factor- Myogenin D
- NBD: Nuclear binding domain
- p14 (ARF): Protein product induced by a variety of oncogenic signals
- PCNA: proliferating cell nuclear antigen
- PGP: P Glycoprotein
- PML : Promyelocytic oncoprotein
- POD : PML oncoprotein domain
- RA: Retinoic acid
- Ras: Rat sarcoma
- Rb: retinoblastoma
- SP1: Stimulatory protein 1
- TGF-beta: Transforming growth factor beta
- TMD: Transmembrane domain
- TNF α : Tumor necrosis factor alpha
- TRAIL: TNF-related apoptosis-inducing ligand
- VCAM-1: Vascular cell adhesion molecule -1
- VEGF: vascular endothelial growth factor
- VER: verapamil

REVIEW OF LITERATURE

Ameloblastoma

Ameloblastomas are with rare exceptions, benign and slow growing epithelial odontogenic neoplasms with locally infiltrative behavior (Yamada et al., 2005)⁽¹⁵²⁾.

Clinical Features of Ameloblastoma:

Ameloblastomas in general are rare in children and have an average range of age between 33-44 years in the United States (Wiseman et al., 2003)⁽¹⁴⁹⁾. Similar age range was recorded also in the Far East (MacDonald-Jankowski et al., 2004)⁽⁸⁸⁾, while in West Africa the mean age showed slight variability (between 26- 40 years) (Ajayi et al., 2005)⁽¹⁾. Maxillary ameloblastomas may be seen in different age mainly up to 46 years (Sugiyama et al., 2004)⁽¹³¹⁾.

All ameloblastomas grow slowly and typically cause no symptoms until a swelling becomes noticeable, however pain was reported in some cases with other signs like difficulty of wearing dentures, displacement, mobility and resorption of teeth, paraesthesia of the inferior dental nerve and rarely ulceration of the mucosa (Omondi et al., 2004)⁽¹⁰⁶⁾.

As the tumor grows it forms a hard, rounded swelling, the slow growth of the tumor allows reactive bone formation to keep pace with it, as a result the jaws may become grossly enlarged and distorted (Torres-Lagares et al., 2005⁽¹³⁵⁾, Sanchis, 2005⁽¹²²⁾).

If the ameloblastoma is neglected, further tumor can perforate the bone and ultimately spread into soft tissue making subsequent excision difficult (Yamada et al., 2005)⁽¹⁵²⁾.

Radiographic Features of Ameloblastoma:

85% of ameloblastomas showed a rounded well defined multilocular cyst like radiolucent areas with well defined margins. The rest of radiographic pictures were variable including a honey comb, soap bubble appearance or rarely a few large radiolucent areas with small daughter cysts and the bony margins were typically scalloped (Velez and Siegel 2004)⁽¹⁴²⁾.

Ameloblastomas infiltrate through medullary bone often without inducing resorption. The radiographic margins are not therefore accurate indicators of the exact involvement of the lesion. Compact cortical bone mainly undergoes pressure resorption rather than invasion also the periosteum is rarely involved (Pinheiro et al., 2005)⁽¹¹²⁾.

The desmoplastic ameloblastoma can resemble a fibro-osseous lesion showing radiographically an irregular radiolucent area containing fine irregular calcifications having indistinct borders others have mixed radiolucent radioopaque appearance (Hirota et al., 2005)⁽⁶⁴⁾.

Microscopic Features

The odontogenic epithelium of ameloblastoma exhibits various patterns, the two main types being follicular and plexiform. Subtypes are acanthomatous, granular-cell, basaloid, desmoplastic and clear cell. As far as is known at present, the histopathological pattern has no bearing on the clinical behavior of an ameloblastoma (Yamada et al., 2005)⁽¹⁵²⁾.

a. Follicular Ameloblastoma: follicular ameloblastomas consist of islands or trabeculae of epithelial cells in odontogenic stroma. These epithelial islands consist of a core of loosely arranged polygonal or angular cells that resemble stellate reticulum surrounded by a well organized single layer of tall columnar ameloblast like cells with nuclei away from the basement membrane (Rapidis et al., 2004)⁽¹¹⁶⁾. Cyst formation sometimes occurs within the epithelial islands of the follicle where it varies from small cysts within a predominantly solid tumor to a completely cystic tumor (Sugiyama et al., 2004)⁽¹³⁰⁾.

Acanthomatous ameloblastomas: acanthomatous ameloblastomas show squamous metaplasia of the central core of epithelium of the tumors follicles, which otherwise resemble the more common follicular type. Keratin formation may be prominent and the tumor may be mistaken for a squamous cell carcinoma (Britt et al., 2005)⁽¹⁶⁾.

Granular cell ameloblastomas: are a rare subtype of follicular ameloblastoma; they usually resemble the more common follicular type, but the epithelium, particularly in the centers of the tumor islands, forms sheets of large eosinophilic granular cells resembling those of other granular cell tumors, this change may be so extensive that the peripheral columnar cells are replaced, making the tumor difficult to recognize in a small biopsy specimen. Granular cell formation was thought to be an aging or degenerative change, but can be seen in ameloblastomas in young persons (Awagu and Vigneswaran 2004)⁽⁵⁾.

Desmoplastic ameloblastomas: Desmoplastic ameloblastomas have been reported that these tumors consist of dense collagenous fibrous tissue in which there are small, irregular islands of neoplastic epithelium (Durmus et al., 2003)⁽⁴¹⁾. These islands are rounded or angular, and may have slender straggling extensions. There is little or no cyst formation, and ameloblast-like cells are typically only present in small foci on the periphery of some islands of epithelium. Stellate reticulum-like tissue is also absent from the interior of the epithelial islands, which consist of densely packed spindle-shaped or polygonal cells. Squamous metaplasia or foci of keratinization may occasionally be seen centrally, and calcification in the fibrous stroma and, occasionally, bone formation is seen (Maresi et al, 2003)⁽⁹²⁾.

Basal cell ameloblastoma: consist of darkly staining cells in a predominantly trabecular pattern with little evidence of palisading at the periphery. Rare examples of extraosseous basal cell ameloblastomas have been mistaken for basal cell carcinomas. However, the latter do not affect the oral cavity (Rozylo-Kalinowska 2002)⁽¹²⁰⁾.